These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27987364)

  • 1. Effect of the Polymorphism of Folylpolyglutamate Synthetase on Treatment of High-Dose Methotrexate in Pediatric Patients with Acute Lymphocytic Leukemia.
    Huang Z; Tong HF; Li Y; Qian JC; Wang JX; Wang Z; Ruan JC
    Med Sci Monit; 2016 Dec; 22():4967-4973. PubMed ID: 27987364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of genetic polymorphisms of FPGS, GGH, and MTHFR on serum methotrexate levels in Chinese children with acute lymphoblastic leukemia.
    Wang SM; Sun LL; Zeng WX; Wu WS; Zhang GL
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):283-9. PubMed ID: 24908438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation analysis of FPGS rs10760502G>a polymorphism with prognosis and MTX-related toxicity in pediatric B-cell acute lymphoblastic leukemia].
    Liu SG; Gao C; Li ZG; Li WJ; Cui L; Zhao XX; Zheng HY; Wu MY; Zhang RD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):291-7. PubMed ID: 24762994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
    Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance.
    Wojtuszkiewicz A; Raz S; Stark M; Assaraf YG; Jansen G; Peters GJ; Sonneveld E; Kaspers GJ; Cloos J
    Int J Cancer; 2016 Apr; 138(7):1645-56. PubMed ID: 26547381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
    Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
    Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia.
    Chae H; Kim M; Choi SH; Kim SK; Lee JW; Chung NG; Cho B; Kim Y
    J Chemother; 2020 Sep; 32(5):251-259. PubMed ID: 32431230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia.
    Wojtuszkiewicz A; Assaraf YG; Hoekstra M; Sciarrillo R; Jansen G; Peters GJ; Pieters R; Sonneveld E; Escherich G; Kaspers GJ; Cloos J
    Haematologica; 2016 Jul; 101(7):e291-4. PubMed ID: 27036162
    [No Abstract]   [Full Text] [Related]  

  • 10. Mutation Screening and Association Study of the Folylpolyglutamate Synthetase (FPGS) Gene with Susceptibility to Childhood Acute Lymphoblastic Leukemia.
    Piwkham D; Siriboonpiputtana T; Beuten J; Pakakasama S; Gelfond JA; Paisooksantivatana K; Tomlinson GE; Rerkamnuaychoke B
    Asian Pac J Cancer Prev; 2015; 16(11):4727-32. PubMed ID: 26107232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia.
    Rots MG; Pieters R; Peters GJ; Noordhuis P; van Zantwijk CH; Kaspers GJ; Hählen K; Creutzig U; Veerman AJ; Jansen G
    Blood; 1999 Mar; 93(5):1677-83. PubMed ID: 10029597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.
    Lopez-Lopez E; Ballesteros J; Piñan MA; Sanchez de Toledo J; Garcia de Andoin N; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pharmacogenet Genomics; 2013 Feb; 23(2):53-61. PubMed ID: 23222202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
    Seidemann K; Book M; Zimmermann M; Meyer U; Welte K; Stanulla M; Reiter A
    Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Kantar M; Kosova B; Cetingul N; Gumus S; Toroslu E; Zafer N; Topcuoglu N; Aksoylar S; Cinar M; Tetik A; Eroglu Z
    Leuk Lymphoma; 2009 Jun; 50(6):912-7. PubMed ID: 19391036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia.
    Barredo JC; Synold TW; Laver J; Relling MV; Pui CH; Priest DG; Evans WE
    Blood; 1994 Jul; 84(2):564-9. PubMed ID: 7517720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia.
    Wang SM; Zeng WX; Wu WS; Sun LL; Yan D
    Leuk Res; 2018 Feb; 65():61-66. PubMed ID: 29306656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.
    He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J
    Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between the methylenetetrahydrofolate reductase gene polymorphism and adverse reactions of high-dose methotrexate in children with acute lymphocytic leukemia].
    Zheng MM; Yue LJ; Chen XW; Wen FQ; Li CG; Yang CL; Xie C; Ding H
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Mar; 15(3):201-6. PubMed ID: 23498762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
    Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
    Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia.
    Laverdière C; Chiasson S; Costea I; Moghrabi A; Krajinovic M
    Blood; 2002 Nov; 100(10):3832-4. PubMed ID: 12411325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.